Biweekly carboplatin-gemcitabine administration in elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Annual Congress 2007 - Therapy of thoracic malignancies Year: 2007
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
Front-line weekly gemcitabine (G) for unfit or elderly patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003
Second-line weekly paclitaxel in advanced nonsmall cell lung cancer (NSCLC) Source: Annual Congress 2003 - Advanced lung cancer treatment Year: 2003
Gemcitabine and cisplatin ( GD) as first line chemotherapy in patients with non-small-cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002
Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Treatment of patients with advanced non-small-cell lung cancer (NSCLC) with erlotinib: results from clinical practice Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Hyper-progressive disease in patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo) Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018
Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease. Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017
Treatment of advanced non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005
Chemotherapy with oral vinorelbine for geriatric patients with advanced non-small cell lung cancer – preliminary results Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006
Phase I trial of lipoplatinÔ and gemcitabine as second line chemotherapy in patients with refractory or resistant advanced non-small-cell lung carcinoma (NSCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 241s Year: 2007
Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001
Chemotherapy with carboplatin and gemcitabine in patients with non resectable stages of non-small cell lung cancer (non-SCLC) Source: Eur Respir J 2007; 30: Suppl. 51, 436s Year: 2007
Serum tumor markers and quality of life before and after platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Docetaxel in combination with cisplatin in patients with advanced non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
A study comparing the efficacy, quality of life and toxicity of cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer in the Indian scenario Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients Year: 2011
Vinorelbin and cisplatin in the treatment of advanced stage non-small cell lung cancer: Indian experience Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008